Home

Charles River Laboratories International, Inc. Common Stock (CRL)

150.33
-17.16 (-10.25%)
NYSE · Last Trade: Aug 6th, 5:51 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close167.49
Open157.18
Bid90.01
Ask150.33
Day's Range150.28 - 162.72
52 Week Range91.86 - 234.90
Volume2,241,266
Market Cap7.58B
PE Ratio (TTM)-250.55
EPS (TTM)-0.6
Dividend & YieldN/A (N/A)
1 Month Average Volume840,651

Chart

About Charles River Laboratories International, Inc. Common Stock (CRL)

Charles River Laboratories International is a global provider of laboratory services that support the pharmaceutical, biotechnology, and medical device industries. The company offers a comprehensive suite of research and development solutions, including essential support for drug discovery, safety assessment, and manufacturing. By providing innovative tools and technologies, as well as expertise in areas such as toxicology and genetic testing, Charles River plays a critical role in advancing biomedical research and helping clients develop and bring new therapies to market efficiently and effectively. Read More

News & Press Releases

Charles River (CRL) Q2 EPS Jumps 11%fool.com
Via The Motley Fool · August 6, 2025
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricingbenzinga.com
Charles River lifts earnings guidance after Q2 beat, citing biotech demand stability, solid DSA performance, and easing regulatory headwinds.
Via Benzinga · August 6, 2025
Which S&P500 stocks are moving on Wednesday?chartmill.com
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · August 6, 2025
Charles River Laboratories (NYSE:CRL) Delivers Impressive Q2
Lab services company Charles River Laboratories (NYSE:CRL) reported Q2 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.03 billion. Its non-GAAP profit of $3.12 per share was 24.6% above analysts’ consensus estimates.
Via StockStory · August 6, 2025
Earnings Scheduled For August 6, 2025benzinga.com
Via Benzinga · August 6, 2025
Charles River Laboratories Announces Second-Quarter 2025 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2025. For the quarter, revenue was $1,032.1 million, an increase of 0.6% from $1,026.1 million in the second quarter of 2024.
Charles River Laboratories (CRL) Reports Earnings Tomorrow: What To Expect
Lab services company Charles River Laboratories (NYSE:CRL) will be announcing earnings results this Wednesday before market open. Here’s what to look for.
Via StockStory · August 4, 2025
Charles River and BioTech Social Inc. Pursue Crowdfunding Partnership
Charles River Laboratories International, Inc. (NYSE: CRL) and BioTech Social Inc. (BSI) today announced the exploration of a potential client-centric collaboration to enable Charles River Incubator (CIP) and Accelerator (CAP) Program participants to access the BioTech Funding Portal, an investment crowdfunding platform for life science companies.
Explore the top gainers and losers within the S&P500 index in today's session.chartmill.com
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · July 24, 2025
These S&P500 stocks are moving in today's sessionchartmill.com
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · July 24, 2025
RPM International Posts Better-Than-Expected Earnings, Joins ICON, MaxLinear, Nasdaq And Other Big Stocks Moving Higher On Thursdaybenzinga.com
Via Benzinga · July 24, 2025
These S&P500 stocks are gapping in today's sessionchartmill.com
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Thursday. Discover the gap up and gap down stocks in the S&P500 index.
Via Chartmill · July 24, 2025
Explore the top gainers and losers within the S&P500 index in today's session.chartmill.com
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.
Via Chartmill · July 22, 2025
Why Are Charles River Laboratories (CRL) Shares Soaring Today
Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 7.5% in the morning session after the company announced a plasmid DNA manufacturing agreement with Elly's Team, a parent-led foundation working to find a cure for a rare genetic disorder. 
Via StockStory · July 22, 2025
Discover which S&P500 stocks are making waves on Tuesday.chartmill.com
Let's delve into the developments on the US markets in the middle of the day on Tuesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via Chartmill · July 22, 2025
D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesdaybenzinga.com
Via Benzinga · July 22, 2025
Tuesday's pre-market session: top gainers and losers in the S&P500 indexchartmill.com
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Via Chartmill · July 22, 2025
Charles River Joins Elly’s Team to Drive Rare Disease Gene Therapy Development
Charles River Laboratories International, Inc. (NYSE: CRL) and Elly’s Team, a parent-led foundation striving to find a cure for Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS), a rare genetic disorder, have announced a plasmid DNA contract development and manufacturing organization (CDMO) agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Elly’s Team accessed established gene therapy CDMO capabilities and advisory services to manufacture critical starting materials for a Phase I clinical trial.
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · July 21, 2025
What's going on in today's session: S&P500 moverschartmill.com
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · July 21, 2025
Monday's session: gap up and gap down stock in the S&P500 indexchartmill.com
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Monday to uncover the stocks that are gapping in the S&P500 index.
Via Chartmill · July 21, 2025
US House Passes Crucial Crypto Bills — From SEC Chair Paul Atkins To Coinbase CEO Brian Armstrong, Here's How Everyone Reactedbenzinga.com
The bid to set clear working rules for the cryptocurrency industry in the U.S. got a booster pill Thursday as the House of Representatives passed key pieces of legislation.
Via Benzinga · July 17, 2025
Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2025 financial results on Wednesday, August 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 6th, at 9:00 a.m. ET.
U.S. Physical Therapy, Evolent Health, Charles River Laboratories, Moderna, and Intuitive Surgical Shares Are Falling, What You Need To Know
A number of stocks fell in the morning session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. 
Via StockStory · July 11, 2025
What's going on in today's session: S&P500 gap up and gap down stockschartmill.com
Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · July 11, 2025